262423-77-8

Basic information

• Product Name: 2,4-Dichloropyridine-3-carboxylic acid
• Synonyms: 2,4-Dichloronicotinc Acid;2,4-Dichloropyridine-3-carboxylic acid;2,4-DICHLORONICOTINIC ACID,98%;2,4-Dichloronicotinic acid;2,4-Dichloropyridine-3-carboxylic acid, 3-Carboxy-2,4-dichloropyridine;2,4- twochlorine nicotinic acid
• CAS NO: 262423-77-8
• Molecular Formula: C₆H₃Cl₂NO₂
• Molecular Weight: 192
• Product Categories: Heterocyclic Compounds
• Mol File: 262423-77-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 166-167°
• Boiling Point: 325.17 °C at 760 mmHg
• Flash Point: 150.458 °C
• Appearance: /
• Density: 1.612 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.606
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 0.79±0.25(Predicted)
• CAS DataBase Reference: 2,4-Dichloropyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichloropyridine-3-carboxylic acid(262423-77-8)
• EPA Substance Registry System: 2,4-Dichloropyridine-3-carboxylic acid(262423-77-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 262423-77-8(Hazardous Substances Data)

Usage

Chemical Properties

off-white powder

Uses

2,4-Dichloropyridine-3-carboxylic Acid is useful for the preparation of prolyl hydroxylase inhibitors or erythropoietin inducing agents.

InChI:InChI=1/C6H3Cl2NO2/c7-3-1-2-9-5(8)4(3)6(10)11/h1-2H,(H,10,11)

Upstream product

• 26452-80-2 2,4-dichloropyridine 
• 124-38-9 carbon dioxide 
• 343781-36-2 2,4-dichloro-3-iodo-pyridine 
• 109-09-1 2-chloropyridine 
• 153034-86-7 2-chloro-4-iodopyridine 
• 78607-36-0 2-chloro-3-iodopyridine 

Downstream Products

• 38025-90-0 2-chloro-6-oxo-1,6-dihydropyridine-3-carboxylic acid 
• 442903-28-8 methyl 2,4-dichloronicotinate 
• 857868-68-9 C₂₇H₂₅Cl₂N₅O₅ 
• 1251287-13-4 5-chloro-6-phenoxy-pyridin-3-yl-methanol 
• 1262132-85-3 {[5-(4-fluoro-3-trifluoromethylphenyl)-7-hydroxy[1,2,4]triazolo[1,5-a]pyridine-8-carbonyl]amino}acetic acid 
• 1262132-93-3 tert-butyl 4-(benzyloxy)-2-chloronicotinate 
• 1262132-94-4 tert-butyl 4-(benzyloxy)-2-hydrazinylnicotinate 
• 1262132-95-5 tert-butyl 7-(benzyloxy)-[1,2,4]triazolo[4,3-a]pyridine-8-carboxylate 
• 1262132-97-7 tert-butyl 7-(benzyloxy)-5-iodo-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylate 
• 1262132-98-8 C₂₅H₂₁F₄N₃O₃ 
• 1262132-99-9 C₂₁H₁₃F₄N₃O₃ 
• 1262133-00-5 C₂₅H₂₀F₄N₄O₄ 
• 1262133-01-6 C₁₈H₁₄F₄N₄O₄ 
• 1262133-02-7 tert-butyl 7-(benzyloxy)-5-(phenylethynyl)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylate 

Relevant articles and documents

BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.

TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT

The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.

Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors

Tumor angiogenesis is mediated by KDR and other VEGFR and PDGFR kinases. Their inhibition presents an attractive approach for developing anticancer therapeutics. Here, we report a series of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted k